| Target Price | HK$9.35 |
| Price | HK$7.09 |
| Potential |
31.92%
register free of charge
|
| Number of Estimates | 26 |
|
26 Analysts have issued a price target Sino Biopharmaceutical 2026 .
The average Sino Biopharmaceutical target price is HK$9.35.
This is
31.92%
register free of charge
HK$12.81
80.68%
register free of charge
HK$5.05
28.77%
register free of charge
|
|
| A rating was issued by 31 analysts: 29 Analysts recommend Sino Biopharmaceutical to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sino Biopharmaceutical stock has an average upside potential 2026 of
31.92%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion HK$ | 31.54 | 36.90 |
| 10.18% | 17.00% | |
| EBITDA Margin | 25.58% | 27.48% |
| 4.14% | 7.41% | |
| Net Margin | 12.12% | 13.67% |
| 36.22% | 12.75% |
28 Analysts have issued a sales forecast Sino Biopharmaceutical 2025 . The average Sino Biopharmaceutical sales estimate is
This results in the following potential growth metrics:
26 Sino Biopharmaceutical Analysts have issued a net profit forecast 2025. The average Sino Biopharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | 0.21 | 0.28 |
| 61.54% | 33.33% | |
| P/E | 25.16 | |
| EV/Sales | 3.14 |
26 Analysts have issued a Sino Biopharmaceutical forecast for earnings per share. The average Sino Biopharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Sino Biopharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


